In the latest trading session, 0.49 million Allarity Therapeutics Inc (NASDAQ:ALLR) shares changed hands as the company’s beta touched -0.07. With the company’s most recent per share price at $0.95 changed hands at -$0.01 or -0.91% at last look, the market valuation stands at $4.21M. ALLR’s current price is a discount, trading about -24209.47% off its 52-week high of $230.94. The share price had its 52-week low at $0.68, which suggests the last value was 28.42% up since then. When we look at Allarity Therapeutics Inc’s average trading volume, we note the 10-day average is 3.98 million shares, with the 3-month average coming to 2.58 million.
Analysts gave the Allarity Therapeutics Inc (ALLR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALLR as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Allarity Therapeutics Inc’s EPS for the current quarter is expected to be 0.
Allarity Therapeutics Inc (NASDAQ:ALLR) trade information
Instantly ALLR was in red as seen in intraday trades today. With action -15.19%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -18.81%, with the 5-day performance at -15.19% in the red. However, in the 30-day time frame, Allarity Therapeutics Inc (NASDAQ:ALLR) is -3.07% down. Looking at the short shares, we see there were 0.66 million shares sold at short interest cover period of 0.44 days.
Allarity Therapeutics Inc (NASDAQ:ALLR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 16.80% of Allarity Therapeutics Inc shares while 2.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 2.83%.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund. With 7.19 shares estimated at $6809.0 under it, the former controlled 0.16% of total outstanding shares. On the other hand, Fidelity Series Total Market Index Fund held about 0.04% of the shares, roughly 1.93 shares worth around $1831.0.
